The Armchair Analyst

The Armchair Analyst

5-minute daily updates on the ASX life-sciences sector.

Recent Articles

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Time to Leverage Up: The Nexalis (ASX: NX1) Story

Apr 24, 2026

•

7 min read

Blue Chipped: What happened to Cochlear (ASX: COH)?

Blue Chipped: What happened to Cochlear (ASX: COH)?

Apr 23, 2026

•

4 min read

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

CAR-T Blanche: Big Pharma Writes Another Billion-Dollar Cheque

Apr 22, 2026

•

4 min read

The Economics of Psychedelic Therapy

The Economics of Psychedelic Therapy

Apr 21, 2026

•

7 min read

Trump Greenlights Psychedelics in the US for PTSD

Trump Greenlights Psychedelics in the US for PTSD

Apr 20, 2026

•

2 min read

My Second Armchair Pick: Emyria (ASX: EMD)

My Second Armchair Pick: Emyria (ASX: EMD)

Apr 20, 2026

•

11 min read

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

A Beacon of Australian Biotech: The Telix (ASX: TLX) Story

Apr 17, 2026

•

9 min read

Riding the Peptidal Wave: Biotech Bounce Back

Riding the Peptidal Wave: Biotech Bounce Back

Apr 16, 2026

•

3 min read

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Betadine II: Lost in Translation. Inside Firebrick Pharma (ASX: FRE) Story

Apr 15, 2026

•

15 min read

When Shares Become the Vote: The 249D-ilemma

When Shares Become the Vote: The 249D-ilemma

Apr 14, 2026

•

7 min read

Telix lights up the deal docket for the ASX biotech sector

Telix lights up the deal docket for the ASX biotech sector

Apr 13, 2026

•

8 min read

While everyone is selling. Big Pharma is buying.

While everyone is selling. Big Pharma is buying.

Apr 10, 2026

•

6 min read

...